Systemic Management of Psoriasis Patients in Indian Scenario: An Expert Consensus

Abstract

Background: Psoriasis is a common inflammatory disease with significant comorbidities, and regardless of its extent, it affects the patients’ quality of life. The various modalities of treating psoriasis comprise topical or systemic medications, phototherapy, and an array of biologic agents. There is a lack of Indian recommendations on the management of psoriasis with these different modalities and challenges faced by the clinicians in day-to-day practice. Aim: To develop India-specific consensus for systemic management of patients with moderate-to-severe psoriasis. Method and Results: A panel of dermatology experts, based on the evidence and international recommendations, coupled with their own clinical experience, developed recommendations for systemic management of patients with moderate-to-severe psoriasis. Conclusion: These recommendations are meant to provide guidance in terms of choice of systemic therapies, dosing, effectiveness, and safety. It also addresses clinical challenges that may be experienced during psoriasis management.

Keywords: Biologics, conventional, Indian consensus, psoriasis, systemic

Introduction

Psoriasis is a common inflammatory disease affecting approximately 2–3% of the world population.[1] In India, the prevalence of psoriasis in adults varies from 0.44 to 2.8%. It is twice more common in males compared to females, and most of the patients are in their third or fourth decade at the time of presentation.[2]

The exact understanding of the etiopathogenesis of this remains unclear. The current consensus is that psoriasis is a predominantly T-cell-mediated disorder, genetically determined, and influenced by environmental factors.[3]

Beyond the physical dimensions of the disease, psoriasis has an extensive emotional and psychosocial effect on the patients,[4] which makes appropriate management mandatory.[5] However, with the added complexities of frequent relapses, nonresponse to conventional treatment, and involvement of difficult-to-treat areas such as palms, soles, and nails, it becomes difficult.[6] The wider range of available treatment options results in a paradox of plenty.[7]

The various modalities of treating psoriasis comprise phototherapy, topical or systemic medications, and an array of biologic agents.[8] Topical therapies (such as corticosteroids, vitamin D analogs) and phototherapy are common first-line treatments. These therapies have limitations due to the lack of long-term efficacy and safety data. Further compliance can be an issue with certain modalities like phototherapy (only 11% of the patients receive the recommended regimen of at least three sessions weekly).[9]

In India, access to phototherapy is a major limiting factor due to the financial burden and time constraints for traveling.

Systemic treatments such as methotrexate (MTX), cyclosporine, acitretin, and small molecules, like apremilast, are widely used in routine clinical practice worldwide.[9,10] Despite their availability and cost-effectiveness, only 0.5–22.6% of the patients are prescribed oral systemic therapies.[9] The main reasons reported in this survey for physicians not initiating or maintaining treatment were related to concerns about the long-term safety or tolerability and efficacy of the currently available oral systemic...

Access this article online
Website: www.idoj.in
DOI: 10.4103/idoj.IDOJ_113_21
Quick Response Code: © 2021 Indian Dermatology Online Journal | Published by Wolters Kluwer - Medknow
therapies. One of the reasons for the under-prescription could be the lack of specific guidelines or recommendations addressing such real-life clinical practice challenges.[11]

Biologics, though useful, are not widely accepted among Indian patients considering their high costs[6] and lack of long-term safety data in the Indian patients for most drugs.[6] Their usage also requires careful screening of eligible patients and continuous monitoring during treatment.[12,13] Counselling a patient, before the initiation of a biologic, is an integral part of management.

The recently published (2019) American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) recommendations highlight the key considerations regarding biologics usage. However, there is a need for country-specific recommendations.[14] Challenges like tuberculosis infection/potential reactivation, therapy cessation, suboptimal dosing due to affordability are specific to India.[9] There is also a lack of Indian recommendations among dermatologists on how and when to transit from one treatment to another in routine clinical practice.[15] Furthermore, there are some challenges with biologics as well. There are some patients who do not respond to certain biologics (primary inefficacy), whereas others who respond initially lose response over time (secondary inefficacy), and the patients who respond but do not reach the desired magnitude of response (partial response).[16]

To address this existing caveat in clinical practice, a group of Indian dermatologists created an India-specific consensus for systemic management of patients with moderate-to-severe psoriasis.

Methodology

An advisory board meeting was organized with a steering committee of the top 10 dermatologists across India. The consensus was obtained on therapeutic approaches and current treatment challenges with respect to the following topics based on the current evidence, guidelines, and their clinical experience [Figure. 1]:

- **Conventional systemic agents**: The systemic agents discussed were the ones most commonly used in India, viz. methotrexate (MTX), cyclosporine (CsA), acitretin, and apremilast.
- **Biologics**: The biologics discussed were the ones currently available in India, viz. etanercept, infliximab, adalimumab (biosimilar), and secukinumab.
- **Clinical challenges with biologics**: The recommendations were focused primarily on the loss of efficacy and transition among the biologics.

**Expert consensus recommendation**

*Therapeutic approaches and current treatment challenges with conventional systemic therapies*

Conventional systemic therapy continues to find use in the majority of psoriasis patients in India because of the ease of administration, low cost, and vast experience of their use.[3]

The final Indian expert consensus recommendations for the appropriate and safe use of conventional drugs are enumerated in Table 1 with some additional points highlighted here.

**Expert consensus recommendations for MTX**

Since its approval in 1972 by the US Food and Drug Administration (FDA), MTX remains a gold standard for the management of psoriasis.[8,21,31]

Recommendations to monitor for hepatotoxicity were individualized to the current Indian practices. It was highlighted that the onset of efficacy is delayed (may take up to 16 weeks to achieve Δ PASI 75) so in the patients who need early onset of action, another drug should be chosen. There was a difference of opinion regarding the relapse and remission with MTX. Post-drug discontinuation, some doctors have experienced relapse immediately, whereas some have not.

**Expert consensus recommendations for CsA**

CsA is a calcineurin inhibitor indicated for the short-course treatment of moderate-to-severe psoriasis. It offers a rapid and significant resolution of the disease, sustained remission, and a positive impact on the quality of life (QoL), making it an ideal choice in a crisis.[32]

However, the treatment effect is short-lived and exacerbation occurs soon after the treatment discontinuation. Methotrexate and acitretin are recommended as sequential treatments after the initial flare is controlled by CsA with an overlap of 1 month to avoid relapse due to discontinuation of CsA. As per the international recommendations, combining cyclosporine with phototherapy is contraindicated. However, the Indian experts recommended the concomitant use of psoralen (P) and ultraviolet (UVA) (PUVA) as well as narrow-band ultraviolet B (NBUVB) with cyclosporine in Indian
Table 1: Expert consensus recommendations for conventional agents[^7^,^8^,^10^,^15^,^17^-^30^]

| Parameters                      | Methotrexate                                           | Cyclosporin                                            | Acrizretin                                              | Apremilast                                              |
|---------------------------------|--------------------------------------------------------|--------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
| **Dose and dosing frequency**   | 7.5-25 mg per week, with folinic acid 5 mg weekly[^a]  | 3 to 5 mg/kg in three divided doses                     | Incremental dose and achieve a target dose of 25 mg daily Max. dose - 50 mg | 30 mg BID Treatment is initiated with a 10 mg morning dose followed by dose escalation as per patients’ tolerance Maybe daily, alternate days or less, used long-term, often years |
| **Duration of therapy**         | Continuous therapy is recommended in responders with regular monitoring | 3-4 months in one treatment cycle                       | Maybe daily, alternate days or less, used long-term, often years | Maybe daily, alternate days or less, used long-term, often years |
| **Screening protocol**          | FBC, LFT, Serum (Sr). creatinine, Sr. electrolytes, Sr. Magnesium, Urine analysis, Lipid profile, Sr. uric acid, HBs-Ag, HCV screening, HIV Blood pressure at two different time points, Pregnancy test | Full blood count, LFT Serum creatinine/eGFR Pregnancy test (urine) Hepatitis B and C[^†] Optional HIV | FBC In women of childbearing age pregnancy must be excluded by negative pregnancy test within 2 weeks before therapy. Effective contraception must be practiced for at least 4 weeks before and during therapy with acitretin, and for 3 years after treatment with acitretin has ceased; LFT; RFT; Lipid profile; Blood sugar levels | Full blood count, LFT Serum creatinine/eGFR Pregnancy test (urine) Hepatitis B and C[^†] Optional HIV |
| **Monitoring protocol**         | Differential blood count, Sr. creatinine BUN; Liver function test after 1, 2, 4, 12 weeks, then every 3 months In case of 3 persistent elevations of LFTs, fibroscan (if possible) or withdrawal methotrexate | At weeks 2,4 then every 4 weeks for 3 months and then 3 monthly FBC, LFT Sr. electrolytes; Sr. creatinine; Urine analysis Sr. magnesium every 6 months; Lipids - every 3 months; Blood pressure - after 2, 4, 6, 8, 10, and 12 weeks, then every month | Liver enzymes every 2-4 weeks for the first 2 months of therapy and then every 3 months; If abnormal results are obtained, weekly checks should be instituted acitretin dose adjusted accordingly; Should be discontinued if transaminases are elevated to 3 times their upper normal limit; Fasting serum cholesterol and triglycerides every 2-4 weeks for the first 2 months and then every 3 months; Blood sugar levels in diabetic patients; X-rays are indicated in patients with musculoskeletal abnormalities; RFTs every 4 to 8 weeks | Full blood count ALT, AST Serum creatinine/eGFR Weight |
| **Efficacy**                    | Psoriasis area and severity index (PASI) 75 response by week 16 with optimal dosing Quality of life: Dermatology life quality index (DLQI) <5 in 16 weeks | PASI: The onset of response by 4 weeks PASI 75 response by 8-12 weeks in 50%-70% Quality of life: DLQI <5 in 6-8 weeks | All or none phenomenon PASI: PASI 75 response in 41% with 30 mg bd dose at 16 weeks | All or none phenomenon PASI: PASI 75 response in 41% with 30 mg bd dose at 16 weeks |

[^a]: Continuous therapy is recommended in responders with regular monitoring.
[^†]: Optional.

Contd...
### Concomitant Medication Indicated

| Parameters |
|------------|
| Methotrexate | Cyclosporin | Acitretin | Apremilast |
| Topical treatment | Topical treatment | Topical treatment | Acitretin |
| Occasional phototherapy* | Methotrexate | Phototherapy | Adalimumab |
| Biologics** | Acitretin | Etanercept | Methotrexate |
| Cyclosporine | A short course of steroids in GPP, Phototherapy (PUVA as well as NBUVB) | Methotrexate | Etanercept |
| Apremilast |

### Relapse and Remission

| Relapse is seen on an average between 3 and 4 months after discontinuation of methotrexate |
| Relapses were seen soon after treatment discontinuation (1-3 months). |
| Although Indian experts recommended a maximum of 2 years of therapy with an adaptation of rotational therapy with cyclosporine, international guidelines recommend a maximum of 1-year therapy with cyclosporine[18] |

| Relapse is seen soon after treatment discontinuation (1-3 months). |
| Relapses were seen soon after treatment discontinuation (1-3 months). |
| Managed by either reintroducing acitretin or switching to other conventional systemic agents or biologics. |

### Safety Concerns

**Adverse Effects**

| Parameters |
|------------|
| Methotrexate | Cyclosporin | Acitretin | Apremilast |
| Very frequent: Nausea, malaise, hair loss |
| Frequent: Elevated transaminases, bone marrow suppression, gastrointestinal ulcers, pneumonitis |
| Occasional: Fever, chills, depression, infections |
| Rare: Nephrotoxicity, liver fibrosis, and cirrhosis |
| Very rare: Interstitial pneumonia, alveolitis |
| Renal failure |
| High blood pressure |
| Gingival hyperplasia |
| Headache |
| Hypertrichosis |
| Hyperlipidemia |
| Hepatotoxicity |
| Teratogenic |
| Mucocutaneous lesions (Cheilitis, dry mouth, nose bleed) |
| Skeletal AEs |
| Hair loss |
| Elevated liver enzymes |
| Elevated cholesterol |
| Diarrhea, increased gastrocolic reflex |
| Depression (In patients with predisposing factors) |
| Weight loss (Withdraw apremilast if weight loss of more than 10% basal weight is seen after the initial period) |
| Upper respiratory tract infection (URTI) |
| Nausea |
| Nasopharyngitis |
| Headache |
| Serious infections (rare) |
| Severe acute infection |
| Hypersensitivity to the active substance (s) or to any of the excipients |
| Pregnancy or breastfeeding |
| Galactose intolerance |
| Lactase deficiency or glucose-galactose Malabsorption |

### Absolute Contraindications

| Parameters |
|------------|
| Methotrexate | Cyclosporin | Acitretin | Apremilast |
| Severe infections |
| Severe liver disease |
| Renal failure |
| Conception (men and women)/breastfeeding |
| Alcohol abuse |
| Bone marrow dysfunction/ hematological changes |
| Immunodeficiency |
| Acute peptic ulcer |
| Significantly reduced lung function |
| Hypersensitivity to methotrexate |
| Kidney dysfunction |
| Uncontrolled arterial hypertension |
| Uncontrolled infection |
| Current or past malignancy (exception nonmelanoma skin cancer) |
| Hypersensitivity to CsA |
| Pregnancy (contraception starting 1 month before treatment, and the patient must wait 3 years after cessation to become pregnant) |
| Severe liver failure |
| Severe kidney failure |
| Allergy to drug components |

---

**Contd...**
patients, especially in recalcitrant situations where the options are limited. This is because the risk of combining the drugs has not been documented in type IV or V skin. As a matter of precaution, this combination is better avoided.

The expert guidance on the use of CsA in children was similar to the available literature evidence.[13-17]

**Actretin: Guidance on the appropriate use in the management of psoriasis**

Actretin is a second-generation synthetic retinoid that was first synthesized 35 years ago and was first introduced 25 years ago in Spain. It holds a unique role in the management of psoriasis because of its different modes of action.[22]

The efficacy of acitretin is dose-dependent, and the response varies from patient to patient.

Caution is recommended on the concomitant use of methotrexate and acitretin, as sporadic severe hepatotoxic reports have been reported. Similarly, a combination of CsA and acitretin is not recommended as this may lead to CsA toxicity. Teratogenicity is a serious concern with acitretin, and adequate monitoring is required, especially in the higher-risk groups.[7,19,20,22,29,30,38]

**Apremilast: Guidance on the appropriate use in the management of psoriasis**

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, approved by the US FDA in 2014, is the first oral drug to receive FDA approval for psoriasis since 1996.[39] Although its exact mechanism of action in psoriasis is unclear, it has shown efficacy in moderate-to-severe plaque psoriasis.[8] The Indian expert consensus was in line with the international literature and guidelines (European S3 Guidelines).[10,15,17] The experts agreed that it works well in mild to moderate psoriasis rather than severe psoriasis. It also improves psoriasis at difficult sites such as palmoplantar, nail, and scalp. They also recommended regular weight monitoring in the patients on apremilast. Depression is mentioned in the summary of product characteristics (SmPC) as a potential side effect, with apremilast, however, the experts were of the opinion that depression is more often reported in patients with predisposing factors. The drug does not seem to be a good choice for arthropathy.

**Practical challenges with conventional systemics**

Clinicians are always in a dilemma about the duration of therapy, due to concerns of toxicity with conventional systemics. The consensus was that the therapy should not be stopped, considering the chronic nature of the disease. Nonetheless, due to safety concerns, the duration of treatment needs to be individualized. The board agreed that the patients can be continued on treatment with strict monitoring protocols or can be considered for discontinuation or tailoring of therapy if sustained remission has been maintained for 6 months.
The criteria for the re-initiation of therapy as suggested by the experts:
• The Dermatology Life Quality Index (DLQI)>5
• Physician Global Assessment (PGA)>2
• The body surface area (BSA)>10
• Psoriasis Area and Severity Index (PASI)>5.

Therapeutic Approaches and Current Treatment Challenges with Biologics

Over the past few years, newer and even more effective biologic therapies with more targeted mechanisms of action have become available to the patients.40

Biologics targeting tumour necrosis factor (TNF-α) were developed first and are often referred to as the first-generation biologics: etanercept, infliximab, and adalimumab. They are indicated in patients with chronic moderate-to-severe psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.41-43

Second-generation biologics emerged from 2009 with antibodies targeting the IL-23/Th17-pathway: ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, and tildrakizumab.

Secukinumab is the only second-generation biologic available in India at present. It is indicated as the first-line systemic in moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.18,44

Eligibility criteria for biologics in psoriasis

Indian dermatologists concurred that biologics are generally administered as per the international guideline recommendations and literature evidence (AAD 2008, AAD 2019, BAD 2017, European S3,) and protocol.7,13,14,17,18,21 Additionally, in line with the international recommendations, biologics are the first-line therapy in patients with a limited disease where there is significant impairment of quality of life. In such scenarios, secukinumab is the preferred biologic, considering the safety and its approval as the first-line systemic indication in patients with moderate-to-severe psoriasis [Figure 2].38

Guidance on the appropriate use of biologics

The recommendations on biologics were limited to etanercept, adalimumab, infliximab, and secukinumab on the basis of their availability in the Indian market and aligned to the international recommendations [Table 2]. The screening and monitoring on the overall biologics were similar across both classes due to TB concerns in India, although the risk is less with the interleukin-17 inhibitor.

Considering that India is a self-pay market, India-specific changes/adaptations have been recommended with regards to the dose and duration of therapy.13 Conversely, the final consensus stated that for optimal benefits, dosing should be as per the drug label.

The proposed ranking of biologics (available in India) in terms of efficacy was as follows:
1. Secukinumab
2. Adalimumab/Infliximab
3. Etanercept.

Clinical challenges with biologics

There is limited evidence on the practical challenges faced with biologics. There is inconsistent data on the criteria to determine the primary failure and secondary failure and the management of psoriasis in such scenarios. The experts agreed that the secondary failure should be when there is
• Loss of PASI 50 response
• DLQI score >5
• Absolute PASI >5
• BSA >10.

In case of secondary failure, one should follow the algorithm as shown in Figure 3 to rule out the other causes.15,20,45,46 The expert recommendations on the above-mentioned issues were based on their clinical experience and literature review [Table 3].
Conclusion

The management of psoriasis has evolved in the last decade with a newer class of biologics marking a watershed in the management of psoriasis. The PASI 90 response is now considered as treatment success instead of PASI 75. Due to the differences in the global health care markets as compared to India, the application of global guidelines to India has been challenging. Thus, there has been a requirement for India-specific recommendations based on the integration of evidence and clinical experience.

It was, therefore, the aim of this expert panel to address issues such as choice of therapy, dosing, effectiveness, and safety. for systemics, biologics. It also addressed the clinical challenges faced with these in the ongoing management of psoriasis with these drugs.

The experts contemplated on each of these points by reviewing the published scientific evidence, guideline recommendations, and combined it with their real-world clinical experience for a structured and individualized approach to the treatment.

Financial support and sponsorship

The advisory board meeting for the formulations of this expert consensus was organized by the Novartis HealthCare Pvt Ltd. However, Novartis has played no role in the decision-making.

Conflicts of interest

There are no conflicts of interest.

References

1. Dogra S, Mahajan R. Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatol Online J 2016;7:471-80.
2. Dogra S, Yadav S. Psoriasis in India: Prevalence and pattern. Indian J Dermatol Venereol Leprol 2010;76:595-601.
3. Kanwar AJ, Yadav S, Dogra S. Psoriasis: What is new in nonbiologic systemic therapy in the era of biologics? Indian J Dermatol Venereol Leprol 2010;76:622-33.
4. Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician 2017;63:278-85.
5. Daudén E, Puig L, Ferrándiz C, Sánchez-Carazo JL, Hernanz-Hermosa JM; Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of
Dermatology and Venerology. J Eur Acad Dermatol Venereol 2016;30(Suppl 2):1-18. 
6. Sarma N. Evidence and suggested therapeutic approach in psoriasis of difficult-to-treat areas: Palmoplantar psoriasis, nail psoriasis, scalp psoriasis, and intertriginous psoriasis. Indian J Dermatol 2017;62:113-22. 
7. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonard CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol 2008;58:826-50. 
8. Armstrong AW, Aldredge L, Yamauchi PS. Managing patients with psoriasis in the busy clinic: Practical tips for health care practitioners. J Cutan Med Surg 2016;20:196-206. 
9. Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: Findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol 2013;149:1180-5. 
10. Afra TP, Razmi TM, Dogra S. Apremilast in psoriasis and beyond: Big hopes on a small molecule. Indian Dermatol Online J 2019;10:1-12. 
11. Feldman SR, Goffe B, Rice G, Mitchell M, Kaur M, Robertson D, et al. The challenge of managing psoriasis: Unmet medical needs and stakeholder perspectives. Am Health Drug Benefits 2016;9:504-13. 
12. Hamadah IR, Al Raddadi AA, Bahamdan KA, Fatani MI, Alnadhiri A, Al Rakham AM, et al. Saudi practical guidelines on biologic treatment of psoriasis. J Dermatol Treat 2015;26:223-9. 
13. Rajagopalan M, Mital A. Biologics use in Indian psoriasis patients. Indian Dermatol Online J 2016;7:489-97. 
14. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019;80:1029-72. 
15. Mrowietz U, de Jong EM, Kragballe K, Langley R, Nast A, Puig L, et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2014;28:438-53. 
16. Vide J, Magina S. Moderate-to-severe psoriasis treatment challenges through the era of biological drugs. An Bras Dermatol 2017;92:668-74. 
17. Nast A, Spuls PI, van der Kraaij G, Gisondi P, Paul C, Ormerod AD, Siaig P, et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IFC. J Eur Acad Dermatol Venereol 2017;31:1951-63. 
18. Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management of psoriasis with systemic non-biological therapies. J Am Acad Dermatol 2020;82:1445-86. 
19. National Institute for Health and Care Excellence (NICE). Psoriasis: Assessment and management: NICE Guideline CG153. Available from: https://www.nice.org.uk/guidance/cg153/resources/psoriasis-assessment-and-management-pdf351006290621701. [Last accessed on 2021 Jul 01]. 
20. Smith CH, Jabbar-Lopez ZK, Yiu ZZ, Bale T, Burden AD, Coates LC, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol 2017;177:628-36. 
21. Raaby L, Zachariae C, Ostensen M, Heickendorff L, Thielsen P, Gronaek H, et al. Methotrexate use and monitoring in patients with psoriasis: A consensus report based on a Danish expert meeting. Acta Derm Venereol 2017;97:426-32. 
22. Carretero G, Ribera M, Belinchón I, Carrascosa JM, Puig L, Ferrandiz C, et al. Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr 2013;104:598-616. 
23. Czarnecka-Operacz M, Sadowska-Przytocka A. The possibilities and principles of methotrexate treatment of psoriasis-The updated knowledge. Postepy Dermatol Alergol 2014;31:392-400. 
24. Kolios AG, Yavalkar N, Anliker M, Boehmcke WH, Borradar L, Conrad C, et al. Swiss S3 guidelines on the systemic treatment of psoriasis vulgaris. Dermatology 2016;232:385-406. 
25. Singh SK, Rai T. Relapse in psoriasis with two different tapering regimens of methotrexate: A randomized open-label controlled study. Indian J Dermatol Venereol Leprol 2015;81:144-7. 
26. Navarro-Millan I, Charles-Schoeman C, Yang S, Bathon JM, Bridges SL Jr, Chen L, et al. Changes in lipoprotems associated with methotrexate or combination therapy in early rheumatoid arthritis: Results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum 2013;65:1430-8. 
27. Colombo MD, Cassano N, Bellia G, Vena GA. Cyclosporine regimens in plaque psoriasis: An overview with special emphasis on dose, duration, and old and new treatment approaches. ScientificWorldJournal 2013;2013:805705. 
28. Griffiths CE, Dubertret L, Ellis CN, Finlay AY, Finzi AF, Ho VC, et al. Ciclosporin in psoriasis clinical practice: An international consensus statement. Br J Dermatol 2004;150(Suppl 67):11-23. 
29. Ormerod AD, Campalani E, Goodfield MJ; BAD Clinical Standards Unit. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol 2010;162:952-63. 
30. Sarkar R, Chugh S, Garg VK. Acitretin in dermatology. Indian J Dermatol Venereol Leprol 2013;79:759-71. 
31. Dogra S, Mahajan R. Systemic methotrexate therapy for psoriasis: Past, present and future. Clin Exp Dermatol 2013;38:573-88. 
32. Griffiths CE, Voorhees JJ. Cyclosporine A in the treatment of psoriasis: A clinical and mechanistic perspective. J Invest Dermatol 1990;95:53S-5S. 
33. Napoliitano M, Megna M, Balato A, Ayala F, Lempo S, Villani A, et al. Systemic treatment of pediatric psoriasis: A review. Dermatol Ther (Heidelb) 2016;6:125-42. 
34. Bulbul Baskan E, Yazici S, Tunali S, Saricaoglu H. Clinical experience with systemic cyclosporine A treatment in severe childhood psoriasis. J Dermatolog Treat 2016;27:328-31. 
35. Dogra S, Kaur I. Childhood psoriasis. Indian J Dermatol Venereol Leprol 2010;76:357-65. 
36. Dogra S, Bishnoi A. Childhood psoriasis: What is new and what is news. Indian J Paediatr Dermatol 2018;19:308-14. 
37. Dogra S, Mahajan R, Narang T, Handa S. Systemic cyclosporine treatment in severe childhood psoriasis: A retrospective chart review. J Dermatolog Treat 2017;28:18-20. 
38. Nast A, Amelunxen L, Augustin M, Boehncke WH, Dressler C, Gaskins M, et al. S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment. J Dtsch Dermatol Ges 2018;16:645-69. 
39. Papp K, Reich K, Leonardi CL, Kirkik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate-to-severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM]) 1). J Am Acad Dermatol 2015;73:37-49. 
40. Porter ML, Lockwood SJ, Kimball AB. Update on biologic
safety for patients with psoriasis during pregnancy. Int J Womens Dermatol 2017;3:21-5.

41. Etanercept (Enbrel) package insert. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/103795s5574s5577lbl.pdf. [Last accessed 2021 Jul 01].

42. Infliximab (Remicade) package insert. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/103772s5389s5391s5394lbl.pdf. [Last accessed on 2021 Jul 01].

43. Adalimumab (Humira) package insert. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125057s415lbl.pdf. [Last accessed on 2021 Jul 01].

44. Secukinumab (Cosentyx) package insert. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125504s035lbl.pdf. [Last accessed on 2021 Jul 01].

45. Owczarczyk-Saczonek A, Owczarek W, Osmola-Mańkowska A, Adamski Z, Placek W, Rakowska A. Secondary failure of TNF-α inhibitors in clinical practice. Dermatol Ther 2019;32:e12760.

46. de la Brassinne M, Ghislain PD, Lambert JL, Lambert J, Segaert S, Willaert F. Recommendations for managing a suboptimal response to biologics for moderate-to-severe psoriasis: A Belgian perspective. J Dermatolog Treat 2016;27:128-33.